All In Biotech

Drug Trial Radar · NCT01981720

Extension Study of PRX-102 for up to 60 Months

A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for up to 60 Months to Adult Fabry Patients

Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Jan 16, 2014

Primary completion

Aug 26, 2020

Study completion Nov 9, 2021

Sponsor

Lead sponsor
ProtalixIndustry
Sponsor type
Industry
Collaborators
Chiesi Farmaceutici S.p.A.
First posted
Nov 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.

Conditions

  • Fabry Disease

Interventions

  • PRX-102 (pegunigalsidase alfa)Biological

    PRX-102 1 mg/kg every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03Time frame: Every two weeks up to 60 months

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Institute of Metabolic Disease

    Dallas, Texas

  • O & O Alpan

    Fairfax, Virginia

  • Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C)

    Asunción, Paraguay

  • Hospital de Dia Quiron Zaragoza

    Zaragoza, Spain

  • The Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.